These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
383 related items for PubMed ID: 14722034
1. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA. J Clin Oncol; 2004 Jan 15; 22(2):262-8. PubMed ID: 14722034 [Abstract] [Full Text] [Related]
2. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J. Cancer; 1999 Dec 01; 86(11):2364-9. PubMed ID: 10590379 [Abstract] [Full Text] [Related]
3. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology Group. J Clin Oncol; 2005 May 20; 23(15):3562-7. PubMed ID: 15908667 [Abstract] [Full Text] [Related]
4. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Argiris A, Li Y, Forastiere A. Cancer; 2004 Nov 15; 101(10):2222-9. PubMed ID: 15452834 [Abstract] [Full Text] [Related]
5. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Shin DM, Glisson BS, Khuri FR, Hong WK, Lippman SM. Semin Oncol; 1998 Apr 15; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061 [Abstract] [Full Text] [Related]
6. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH, Southwest Oncology Group, Head and Neck Working Group. Cancer; 2006 Jul 15; 107(2):319-27. PubMed ID: 16779801 [Abstract] [Full Text] [Related]
7. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H. J Clin Oncol; 2005 Dec 01; 23(34):8636-45. PubMed ID: 16275937 [Abstract] [Full Text] [Related]
8. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, Alafaci E, Scimone A, Spano F, Spitaleri G. Oral Oncol; 2004 May 01; 40(5):525-31. PubMed ID: 15006626 [Abstract] [Full Text] [Related]
9. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A. Jpn J Clin Oncol; 2009 Apr 01; 39(4):225-30. PubMed ID: 19211574 [Abstract] [Full Text] [Related]
10. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Recondo G, Armand JP, Tellez-Bernal E, Domenge C, Belehradek M, De Vathaire F, Wibault P, Richard JM, Cvitkovic E. Laryngoscope; 1991 May 01; 101(5):494-501. PubMed ID: 1709437 [Abstract] [Full Text] [Related]
11. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R. Anticancer Res; 2006 May 01; 26(1B):585-90. PubMed ID: 16739325 [Abstract] [Full Text] [Related]
12. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Lawhorn K, Hong WK, Lippman SM. Semin Oncol; 1997 Dec 01; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263 [Abstract] [Full Text] [Related]
13. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Benasso M, Ponzanelli A, Merlano M, Numico G, Ricci I, Vigo V, Grossi F, Amadori D, Cavallo G, Capaccetti B, Taveggia P, Boni L, Rosso R. Acta Oncol; 2006 Dec 01; 45(2):168-74. PubMed ID: 16546862 [Abstract] [Full Text] [Related]
14. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW. Cancer; 2002 Apr 15; 94(8):2224-31. PubMed ID: 12001121 [Abstract] [Full Text] [Related]
15. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Hitt R, Jimeno A, Millán JM, Castellano D, Cortés-Funes H. Cancer; 2004 Aug 15; 101(4):768-75. PubMed ID: 15305408 [Abstract] [Full Text] [Related]
16. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck. Uygun K, Bilici A, Karagol H, Caloglu M, Cicin I, Aksu G, Fayda M, Uzunoglu S. Cancer Chemother Pharmacol; 2009 Aug 15; 64(3):601-5. PubMed ID: 19123002 [Abstract] [Full Text] [Related]
17. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G. Anticancer Res; 2005 Aug 15; 25(6C):4445-9. PubMed ID: 16334124 [Abstract] [Full Text] [Related]
18. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate. Amrein PC, Fabian RL. Laryngoscope; 1992 Aug 15; 102(8):901-6. PubMed ID: 1379664 [Abstract] [Full Text] [Related]
19. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K. J Clin Oncol; 2007 Oct 20; 25(30):4800-5. PubMed ID: 17947728 [Abstract] [Full Text] [Related]
20. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study. Schena M, Barone C, Birocco N, Dongiovanni D, Numico G, Colantonio I, Bertetto O. Cancer Chemother Pharmacol; 2005 Mar 20; 55(3):271-6. PubMed ID: 15592837 [Abstract] [Full Text] [Related] Page: [Next] [New Search]